After another milestone year, here are our picks for the top-five biggest deals in the world of biosimilars in 2016: 1) As we reported in January 2016, Mylan N.V. and Momenta Pharmaceuticals, Inc. entered into an exclusive agreement to jointly develop, manufacture, and commercialize six of Momenta’s current biosimilar medications,…
AstraZeneca announced today that it has entered licensing agreements with LEO Pharma to develop and commercialize tralokinumab, a biologic that has completed a Phase IIb trial for atopic dermatitis, and brodalumab, which is under regulatory review to treat plaque psoriasis. Under the terms of the tralokinumab agreement, LEO Pharma will…